Insights

Healthy longevity has many facets. The breadth of our past and current work illustrates the diversity of the insights that are relevant to this topic.

Dramatic increase in use of the word “healthspan” in biomedical literature. The cumulative number of Pubmed indexed articles annotated with “healthspan” or “health span” in the title or abstract is shown by year. A total of 929 articles were returned. Date of search: July 15, 2018. Adapted from Kaeberlein, M. How healthy is the healthspan concept? GeroScience 40, 361–364 (2018).

https://doi.org/10.1007/s11357-018-0036-9

chart

The Longevity and Anti-Senescence Therapy market size is valued at $27.11 billion in 2023 and is predicted to reach $44.92 billion by the year 2031 at a 6.8% CAGR during the forecast period. The growth of the longevity and anti-senescence therapy market size is driven by increase in prevalence of chronic diseases globally, rise in popularity of anti-aging products, and advancements in AI-driven medical technology. Increase in ageing populations in the US, Japan and Europe contributes to market potential.

Increasing number of research and investment activities in the development of longevity and anti-senescence therapies and increase in demand for cell-based assays is expected to provide lucrative opportunities for the longevity industry growth. Another key aspect is the rising adoption of advanced technologies such as gene therapy, stem cell, and senolytics drug therapy in multiple age-related diseases. In this decade, longevity longevity will be undergoing a period of rapid, disruptive change as ageing is becoming recognised as the cause of age-related diseases, with advanced therapies developed to stop and potentially reverse cellular ageing, which will have a dramatic effect on people’s life expectancy. The market for longevity is emerging; and those working with or investing in advanced therapeutics choosing modalities with the most promising scientific and commercial potential can expect large gains.

Market data source: C Sajeev S.C., Deshmukh R, Allied market Research 2022

Articles & Videos

The Fashionable Molecule for Healthy Longevity
CBD (cannabidiol) has risen significantly in profile in recent years. Its growing popularity among researchers, patients and casual users alike merits a discussion of its therapeutic promise. This paper provides an overview of clinical applications of CBD that are currently under investigation by the pharmaceutical industry and offers some remarks on the future prospects of CBD-based products.
Let's Hold the Gains: What are we learning from COVID-19 crisis and how we see these lessons bearing fruit?
In the midst of an unprecedented health emergency, it may seem strange to speak of ‘gains’, i.e. gains from our experience in combatting COVID-19. The loss of loved ones through COVID-19 is a terrible tragedy and no ‘gain’ or advances in our approach can ever outweigh this loss. But in this context, we face an even greater responsibility to be clear on what we are learning from this crisis and how we see these lessons can benefit others in the future post-COVID world.
COVID-19: Planning for the future
Dr Charles Alessi speaks about COVID-19 "exit strategy" based on the use of telemedicine, secondary use of medical data and global hypercollaboration at Public Policy Projects.
From Precision Medicine to Precision Health: If we use the phrase “precision medicine” what do you think of?
For many, perhaps most people, genomic tests for targeted cancer drugs and precise diagnosis of rare, inherited disease will be some of the applications that spring first to mind.

Tremendous advances, certainly. The ability to distinguish between tumour types at a molecular level and design the cocktail of therapies most likely to combat it is one of the wonders of the last decade.
Translating the Life Sciences into Human Longevity
Lecture by Prof. Richard Barker at Gowing Life (Oxford, UK)
Barker's business career has included work in both Europe and the US. He worked for McKinsey between 1980 and 1993, where he headed the European Healthcare practice and advised UK, Swiss and US pharmaceutical companies. He also helped establish 'London First', a public/private initiative that aims to enhance London’s status as a global city...

Useful Resources

Eds. Moskalev A., Stambler I., Zhavoronkov A. (2023) Artificial Intelligence for Healthy Longevity. Springer, Volume 19 ISBN: 9783031351754

Scott, A.J. (2021) The longevity Economy. Health Policy 2, 12 E828-E-835, 2021. Available from doi: https://doi.org/10.1016/S2666-7568(21)00250-6

Zhavoronkov, A., Bischof, E. & Lee, KF (2021) Artificial intelligence in longevity medicine. Nat Aging 1, 5–7. Available from doi: https://doi.org/10.1038/s43587-020-00020-4

Barker R., Stambler I. (2019) Clinical Translation Acceleration. In: Gu D., Dupre M. (eds) Encyclopedia of Gerontology and Population Aging. Springer, Cham Available from doi: https://doi.org/10.1007/978-3-319-69892-2

Shvarova O.Y. (2019) Health Technology Assessment of Aging Therapies. In: Gu D., Dupre M. (eds) Encyclopedia of Gerontology and Population Aging. Springer, Cham Available from doi: https://doi.org/10.1007/978-3-319-69892-2

Barker, R. (2016). Bioscience - lost in translation: How precision medicine closes the innovation gap. Oxford University Press ISBN: 9780198737780

Barker, R. (2010) 2030 - The Future of Medicine: Avoiding a Medical Meltdown. Oxford University Press ISBN: 9780199600663; ebook Available from doi: https://doi.org/10.1093/med/9780199600663.003.0001